Vitrolife AB (publ) (“Vitrolife”) today announced that following a strategic review it will execute a restructuring program of its genetic services business. The program is targeting annualised savings of SEK 65 million, expected to have a positive impact in the first half of 2026, and to reach full effect by the end of the third quarter 2026. Furthermore, Vitrolife will record a goodwill impairment of SEK 5.4 billion in Q4 2025, related to the Igenomix acquisition.As part of the restructuring ...
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1 2025. The presentation will be held in English.
Time: Thursday 24 April, 2025 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy (ht...
The shareholders of Vitrolife AB (publ) are hereby invited to attend the Annual General Meeting of shareholders on 29 April 2025 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm.
Shareholders who wish to attend the Annual General Meeting must:
- be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on 17 April 2025; and
- notify their attendance in accordance with the instructions in t...
Vitrolife Group is aware that a PGT-A class action lawsuit has been filed against Vitrolife AB (publ), Vitrolife Inc and Igenomix USA, Inc in the court of the Southern District of Florida, although no formal complaint has been served yet. During the fourth quarter of 2024, similar class actions were initiated in the US against other peer companies providing PGT-A testing services. Vitrolife Group will, together with our legal counsel in the US, evaluate the class action and its potential scope a...
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) in einer aktuellen Aktienanalyse unter die Lupe.
Gute Neuigkeiten für Vitrolife, einen skandinavischen Spezialisten für die Reproduktionsmedizin. [mehr]
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) unter die Lupe.
Mit einem Plus von zwischenzeitlich gut acht Prozent habe sich die Aktie von Vitrolife am Donnerstag zurückgemeldet. [mehr]
Mit einem Plus von zwischenzeitlich gut acht Prozent hat sich die Aktie von Vitrolife am Donnerstag zurückgemeldet. Auslöser für den Kurssprung beim Papier des schwedischen Spezialisten für die Reproduktionsmedizin waren die Zahlen zum vierten Quarta...
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2024. The presentation will be held in English.
Time: Thursday 30 January, 2025 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: ...
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) unter die Lupe.
Der skandinavische Reproduktionsmedizin-Spezialist Vitrolife habe am Donnerstag mit den Zahlen zum dritten Quartal die Markterwartungen leicht verfehlt. [mehr]
Die Erstattung von Fruchtbarkeitsbehandlungen in den USA ist eines der zentralen Themen im Wahlkampf. Vitrolife könnte so oder so zum Gewinner avancieren.Kamala Harris vs. Donald Trump. In den USA liefern sich die beiden US-Präsidentschaftskandidaten...
Die Erstattung von Fruchtbarkeitsbehandlungen in den USA ist eines der zentralen Themen im Wahlkampf. Vitrolife könnte so oder so zum Gewinner avancieren.
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q3, 2024. The presentation will be held in English.
Time: Thursday 24 October, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy |...
The following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025:
Niels Jacobsen, appointed by William Demant Invest A/S
Patrik Tigerschiöld, appointed by Bure Equity AB
Patricia Hedelius, appointed by AMF Fonder & Pension
Jón Sigurdsson, Chairman of the Board
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at ...
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) unter die Lupe.
Im US-Wahlkampf zwischen Kamala Harris und Donald Trump werde die flächendeckende Erstattung von Maßnahmen zur künstlichen Befruchtung wie der In-vitro-Fertilisation (IVF) weiterhin stark diskutiert. [mehr]
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) unter die Lupe.
Der US-Wahlkampf gehe in die heiße Phase. [mehr]
Kulmbach (www.aktiencheck.de) - Vitrolife-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Vitrolife AB (ISIN: SE0011205202, WKN: A2JLT3, Ticker-Symbol: VTFN, NASDAQ Stockholm-Symbol: VITR) unter die Lupe.
US-Präsidentschaftskandidat Donald Trump sei mit einem überraschenden Wahlkampfversprechen vorgeprescht. [mehr]
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q2, 2024. The presentation will be held in English.
Time: Wednesday 17 July, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | V...
The Global Sperm Count Test Market Size was Valued at USD 2.1 Billion in 2023 and the Worldwide Sperm Count Test Market Size is Expected to Reach USD 3.98 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Fertility Focus Inc, Vitrolife AB, Hamilton Thorne, ExSeed health, AB ANALITICA s.r.l., Medical Electronic Systems, Andrology Solutions, DxNow, Artron Laboratories Inc, Olympus Corporation Inc, Mojo, MICROPTIC, Thermo Fisher Scienti...
The correction concerns a clarification in the agenda that item 13 of the agenda also covers the election of an auditor.
The shareholders of Vitrolife AB (publ), corporate identity number 556354-3452
(‘the Company’) are hereby invited to attend the Annual General Meeting of shareholders on Thursday 25 April 2024 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm.
Four weeks before the Annual General Meeting, Vitrolife AB (publ)...
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1, 2024. The presentation will be held in English.
Time: Thursday 18 April, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | V...
The shareholders of Vitrolife AB (publ), corporate identity number 556354-3452
(‘the Company’) are hereby invited to attend the Annual General Meeting of shareholders on Thursday 25 April 2024 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm.
Shareholders who wish to attend the Annual General Meeting must:
-be recorded in the share register prepared by Euroclear Sweden AB relating to the circumstances on 17 April 2024; and
-no...
